Canine cutaneous and systemic histiocytosis

Reactive histiocytosis of dermal dendritic cells

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Canine histiocytic proliferative disorders include reactive diseases such as cutaneous and systemic histiocytosis and neoplastic diseases such as cutaneous histiocytoma and localized and disseminated histiocytic sarcoma (malignant histiocytosis). Their etiology and pathogenesis are unknown. Canine cutaneous and systemic histiocytosis target the skin and subcutis and have similar clinical behavior. Systemic histiocytosis also affects other organ systems. Clinicopathologic and phenotypic features of canine cutaneous and systemic histiocytosis were examined in this study. Canine cutaneous (18 cases) and systemic (26 cases) histiocytosis were characterized by angiocentric, pleocellular accumulations consisting of CD1+, CD11c+, MHC II+, CD4+, and Thy-1+ (CD90) activated dermal dendritic antigen-presenting cells (APC) with admixed CD3+, CD8+, TCRαβ+ T lymphocytes, and neutrophils. Hence, canine cutaneous and systemic histiocytosis represent two clinical manifestations of a reactive proliferation of dermal dendritic cells. Cultures and special stains failed to identify infectious agents. Canine reactive histiocytoses respond to immunosuppressive therapy (cyclosporine A or leflunomide). Therefore, immune-dysregulatory mechanisms are likely to be involved. Spontaneous reactive histiocytoses are frequently seen in dogs, and they constitute an excellent model to study pathologic mechanisms involved in reactive proliferations of dermal dendritic APC.

Original languageEnglish (US)
Pages (from-to)40-48
Number of pages9
JournalAmerican Journal of Dermatopathology
Volume22
Issue number1
DOIs
StatePublished - Feb 2000

Fingerprint

Histiocytosis
Langerhans Cells
Canidae
Skin
Histiocytic Sarcoma
leflunomide
Antigen-Presenting Cells
Dendritic Cells
Benign Fibrous Histiocytoma
Adjustment Disorders
Immunosuppressive Agents
Cyclosporine
Neutrophils
Coloring Agents
Dogs
T-Lymphocytes

Keywords

  • Animal
  • Antigen-presenting cells
  • CD1
  • CD11c
  • CD90
  • Dermal dendritic cells
  • Disease model
  • Dog
  • Histiocytosis
  • Immunedysregulation
  • Immunohistochemistry
  • Immunophenotyping
  • Langerhans cells
  • Lymphoid organs
  • Skin

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Dermatology

Cite this

@article{e40f053fc45d449fb82ae0fdd647aec3,
title = "Canine cutaneous and systemic histiocytosis: Reactive histiocytosis of dermal dendritic cells",
abstract = "Canine histiocytic proliferative disorders include reactive diseases such as cutaneous and systemic histiocytosis and neoplastic diseases such as cutaneous histiocytoma and localized and disseminated histiocytic sarcoma (malignant histiocytosis). Their etiology and pathogenesis are unknown. Canine cutaneous and systemic histiocytosis target the skin and subcutis and have similar clinical behavior. Systemic histiocytosis also affects other organ systems. Clinicopathologic and phenotypic features of canine cutaneous and systemic histiocytosis were examined in this study. Canine cutaneous (18 cases) and systemic (26 cases) histiocytosis were characterized by angiocentric, pleocellular accumulations consisting of CD1+, CD11c+, MHC II+, CD4+, and Thy-1+ (CD90) activated dermal dendritic antigen-presenting cells (APC) with admixed CD3+, CD8+, TCRαβ+ T lymphocytes, and neutrophils. Hence, canine cutaneous and systemic histiocytosis represent two clinical manifestations of a reactive proliferation of dermal dendritic cells. Cultures and special stains failed to identify infectious agents. Canine reactive histiocytoses respond to immunosuppressive therapy (cyclosporine A or leflunomide). Therefore, immune-dysregulatory mechanisms are likely to be involved. Spontaneous reactive histiocytoses are frequently seen in dogs, and they constitute an excellent model to study pathologic mechanisms involved in reactive proliferations of dermal dendritic APC.",
keywords = "Animal, Antigen-presenting cells, CD1, CD11c, CD90, Dermal dendritic cells, Disease model, Dog, Histiocytosis, Immunedysregulation, Immunohistochemistry, Immunophenotyping, Langerhans cells, Lymphoid organs, Skin",
author = "Affolter, {Verena K} and Moore, {Peter F}",
year = "2000",
month = "2",
doi = "10.1097/00000372-200002000-00009",
language = "English (US)",
volume = "22",
pages = "40--48",
journal = "American Journal of Dermatopathology",
issn = "0193-1091",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Canine cutaneous and systemic histiocytosis

T2 - Reactive histiocytosis of dermal dendritic cells

AU - Affolter, Verena K

AU - Moore, Peter F

PY - 2000/2

Y1 - 2000/2

N2 - Canine histiocytic proliferative disorders include reactive diseases such as cutaneous and systemic histiocytosis and neoplastic diseases such as cutaneous histiocytoma and localized and disseminated histiocytic sarcoma (malignant histiocytosis). Their etiology and pathogenesis are unknown. Canine cutaneous and systemic histiocytosis target the skin and subcutis and have similar clinical behavior. Systemic histiocytosis also affects other organ systems. Clinicopathologic and phenotypic features of canine cutaneous and systemic histiocytosis were examined in this study. Canine cutaneous (18 cases) and systemic (26 cases) histiocytosis were characterized by angiocentric, pleocellular accumulations consisting of CD1+, CD11c+, MHC II+, CD4+, and Thy-1+ (CD90) activated dermal dendritic antigen-presenting cells (APC) with admixed CD3+, CD8+, TCRαβ+ T lymphocytes, and neutrophils. Hence, canine cutaneous and systemic histiocytosis represent two clinical manifestations of a reactive proliferation of dermal dendritic cells. Cultures and special stains failed to identify infectious agents. Canine reactive histiocytoses respond to immunosuppressive therapy (cyclosporine A or leflunomide). Therefore, immune-dysregulatory mechanisms are likely to be involved. Spontaneous reactive histiocytoses are frequently seen in dogs, and they constitute an excellent model to study pathologic mechanisms involved in reactive proliferations of dermal dendritic APC.

AB - Canine histiocytic proliferative disorders include reactive diseases such as cutaneous and systemic histiocytosis and neoplastic diseases such as cutaneous histiocytoma and localized and disseminated histiocytic sarcoma (malignant histiocytosis). Their etiology and pathogenesis are unknown. Canine cutaneous and systemic histiocytosis target the skin and subcutis and have similar clinical behavior. Systemic histiocytosis also affects other organ systems. Clinicopathologic and phenotypic features of canine cutaneous and systemic histiocytosis were examined in this study. Canine cutaneous (18 cases) and systemic (26 cases) histiocytosis were characterized by angiocentric, pleocellular accumulations consisting of CD1+, CD11c+, MHC II+, CD4+, and Thy-1+ (CD90) activated dermal dendritic antigen-presenting cells (APC) with admixed CD3+, CD8+, TCRαβ+ T lymphocytes, and neutrophils. Hence, canine cutaneous and systemic histiocytosis represent two clinical manifestations of a reactive proliferation of dermal dendritic cells. Cultures and special stains failed to identify infectious agents. Canine reactive histiocytoses respond to immunosuppressive therapy (cyclosporine A or leflunomide). Therefore, immune-dysregulatory mechanisms are likely to be involved. Spontaneous reactive histiocytoses are frequently seen in dogs, and they constitute an excellent model to study pathologic mechanisms involved in reactive proliferations of dermal dendritic APC.

KW - Animal

KW - Antigen-presenting cells

KW - CD1

KW - CD11c

KW - CD90

KW - Dermal dendritic cells

KW - Disease model

KW - Dog

KW - Histiocytosis

KW - Immunedysregulation

KW - Immunohistochemistry

KW - Immunophenotyping

KW - Langerhans cells

KW - Lymphoid organs

KW - Skin

UR - http://www.scopus.com/inward/record.url?scp=0033955740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033955740&partnerID=8YFLogxK

U2 - 10.1097/00000372-200002000-00009

DO - 10.1097/00000372-200002000-00009

M3 - Article

VL - 22

SP - 40

EP - 48

JO - American Journal of Dermatopathology

JF - American Journal of Dermatopathology

SN - 0193-1091

IS - 1

ER -